CYP3A substrates/inhibitors
|
|
|
Alpha‐1‐adrenoreceptor antagonists |
Alfuzosin |
Hypotension, dizziness |
Ergot derivatives |
Dihydroergotamine Ergonovine Ergotamine Methylergonovine |
Peripheral vasospasm or ischemia |
Gastrointestinal motility agents |
Cisapride |
Cardiac arrhythmia, QT prolongation |
3‐Hydroxy‐3‐methyl‐ glutaryl‐coenzyme A reductase inhibitors (statins) |
Atorvastatin* Lovastatin Simvastatin |
Myopathy, rhabdomyolysis |
Neuroleptics |
Pimozide |
Cardiac arrhythmia |
Oral contraceptives†
|
Drospirenone |
Hyperkalemia |
Phosphodiesterase type 5 enzyme inhibitors†
|
Sildenafil Tadalafil |
Visual abnormalities, hypotension, prolonged erection, syncope |
Sedatives |
Midazolam Triazolam |
Prolonged sedation, respiratory depression |
CYP3A inducers
|
|
|
Anticonvulsants†
|
Carbamazepine Phenobarbital Phenytoin |
Reduced DAA levels with potentially reduced antiviral efficacy and increased drug resistance |
Antimycobacterials |
Rifampin |
Herbal products |
St. John's wort |
|
|
|